The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs

Giuseppe Palasciano, Piero Portincasa, Vincenzo Palmieri, Daniela Ciani, Gianluigi Vendemiale, Emanuele Altomare

Research output: Contribution to journalArticle

Abstract

The efficacy of the antioxidant silymarin in preventing psychotropic drug-induced hepatic damage was evaluated in a double-blind, placebo-controlled study. Sixty patients receiving chronic psychotropic drug therapy were randomly divided into four groups and were treated for 90 days with silymarin or placebo as follows: group IA-treatment with psychotropic drugs and silymarin, 800 mg/d; group IB-treatment with psychotropic drugs and placebo; group IIA-suspension of psychotropic drugs plus treatment with silymarin, 800 mg/d; and group IIB-suspension of psychotropic drugs plus treatment with placebo. Serum levels of malon-dialdehyde (the end product of the oxidation of polyunsaturated fatty acids) and the indices of hepatocellular function were assessed in each patient at baseline (day 0), on days 15, 30, 60, and 90, and 1 month after the completion of treatment. Our data show that silymarin, when used at submaximal doses, reduces the lipoperoxidative hepatic damage that occurs during treatment with butyrophenones or phenothiazines. The study results also suggest that increased lipoperoxidation may contribute to psychotropic drug-induced hepatotoxicity.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalCurrent Therapeutic Research
Volume55
Issue number5
DOIs
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs'. Together they form a unique fingerprint.

Cite this